These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31836141)

  • 21. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
    Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
    Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
    Gong S; Xu D; Zhu J; Zou F; Peng R
    Cell Physiol Biochem; 2018; 47(2):680-693. PubMed ID: 29794421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.
    Wiesenauer CA; Yip-Schneider MT; Wang Y; Schmidt CM
    J Am Coll Surg; 2004 Mar; 198(3):410-21. PubMed ID: 14992744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence.
    Huang P; Zhuang B; Zhang H; Yan H; Xiao Z; Li W; Zhang J; Tang Q; Hu K; Koeffler HP; Wang J; Yin D
    Clin Cancer Res; 2015 Oct; 21(19):4420-30. PubMed ID: 26059188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-molecule High-throughput Screening Identifies an MEK Inhibitor PD198306 that Enhances Sorafenib Efficacy via MCL-1 and BIM in Hepatocellular Carcinoma Cells.
    Hong J; Zheng W; Cai X
    Comb Chem High Throughput Screen; 2023; 26(7):1364-1374. PubMed ID: 36043792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
    Yang C; Qin S
    Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
    Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
    Zhong L; Yang S; Jia Y; Lei K
    J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
    Ma D; Wang J; Liu L; Chen M; Wang Z
    BMC Cancer; 2020 Sep; 20(1):936. PubMed ID: 32993568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
    Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
    J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.